Get the Stockscreener App
0.71
0.67%
-0.0048
After Hours:
.72
0.01
+1.41%
Nektar Therapeutics stock is traded at $0.71, with a volume of 3.04M.
It is down -0.67% in the last 24 hours and up +14.94% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$0.7148
Open:
$0.7076
24h Volume:
3.04M
Relative Volume:
1.23
Market Cap:
$119.48M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-0.4863
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+10.59%
1M Performance:
+14.94%
6M Performance:
-44.53%
1Y Performance:
-59.43%
1-Day Range:
$0.6597
$0.7366
1-Week Range:
$0.57
$0.7366
52-Week Range:
$0.432
$1.855
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
0.71 | 119.48M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com
Nektar: Q1 Earnings Snapshot - The Washington Post
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timelines | NKTR Stock News - GuruFocus
Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses Estimate, Revenue Falls Short at $10.5 Million - GuruFocus
Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider
Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus
Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq
Nektar Therapeutics Reports First Quarter 2025 Financial Results - PR Newswire
Unmet Needs in Atopic Dermatitis and the Impact of Roflumilast Cream, with Raj Chovatiya, MD, PhD - HCPLive
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com
Nektar Therapeutics's Earnings: A Preview - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal
Nektar to Announce Financial Results for the First Quarter on Th - GuruFocus
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets | NKTR Stock News - GuruFocus
Upcoming Nektar Q1 2025 Earnings Call: CEO Howard Robin to Present Financial Results May 8 - Stock Titan
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com
Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN
Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN
Sector Update: Health Care - TradingView
Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance
Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance
Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga
Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - marketscreener.com
Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India
Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider
Jefferies Upgrades Nektar (NKTR) with Optimistic Outlook on Phase 2b Study | NKTR Stock News - GuruFocus
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nektar Therapeutics Stock (NKTR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
Feb 19 '25 |
Sale |
1.01 |
11,040 |
11,150 |
324,292 |
| ROBIN HOWARD W | President & CEO |
Feb 19 '25 |
Sale |
1.01 |
23,774 |
24,012 |
1,086,901 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):